Highlights
- Agilent reported fiscal third quarter revenue of $1,878 million, up 8%, with GAAP diluted earnings per share of $1.28 versus $1.18.
- Income from operations rose 23% to $444 million, and GAAP operating margin improved to 23.6% from 20.7% a year earlier.
- The company closed its $950 million Biocare acquisition on June 24 and issued $600 million of 4.90% senior notes due 2032.
- Management raised fiscal 2026 revenue guidance to $7.49 billion to $7.51 billion and non-GAAP earnings per share guidance to $6.18 to $6.21.
Agilent Technologies (NYSE:A) shares were trading near their 52-week high at USD 177.53 on October 21, 2026, up 2.61%. The life sciences and diagnostics group closed a $950 million pathology acquisition in late June, issued a bond a day later, and reported fiscal third quarter results on August 31 with a higher full-year outlook.
Based in Santa Clara, California, Agilent was incorporated in Delaware in 1999 and describes itself as a global leader in life sciences, diagnostics and applied markets, selling instruments, software, services and consumables across the laboratory workflow. It reports three segments: Life Sciences and Diagnostics Markets, which spans liquid chromatography, genomics, pathology and its Agilent Advanced Therapeutics oligonucleotide manufacturing business; Agilent CrossLab, which covers services and consumables; and Applied Markets, whose instruments serve food, environmental and chemical testing. Its fiscal year ends October 31, and its headcount is about 18,200.
Revenue Growth and Wider Margins Across All Three Segments
Revenue for the three months ended July 31, 2026 reached $1,878 million, up 8% from $1,738 million. Every segment and region grew. Life Sciences and Diagnostics Markets rose 11% to $746 million on strength in pharmaceutical and diagnostics customers, while academia and government declined. Agilent CrossLab grew 6% to $786 million, and Applied Markets grew 7% to $346 million, with chemical and advanced materials strong and food flat.
GAAP net income was $362 million, or $1.28 per diluted share, compared with $336 million, or $1.18. Gross margin widened to 55.5% from 51.1%, helped by volume, price increases, mix and a net benefit from tariff refunds, which added about one percentage point to operating margin. Costs rose too: selling, general and administrative expenses climbed 14% to $475 million and research and development 10% to $123 million. The tax provision was $82 million against $30 million a year earlier, which included a $28 million reserve release.
Over nine months, revenue was $5,511 million, up 8%, and operating cash flow was $1,064 million versus $1,014 million.
Biocare Deal, New Notes and Capital Returns
On June 24, 2026, Agilent acquired Biocare for net consideration of $950 million, adding pathology solutions to its Life Sciences and Diagnostics Markets segment. On June 25 it issued $600 million of 4.90% senior notes due January 15, 2032, priced at 99.968% of principal. Cash and equivalents stood at $1,758 million on July 31, compared with $1,789 million at October 31, 2025, and nothing was drawn on its $1.5 billion credit facility.
The company paid a quarterly dividend of $0.255 per share, or $72 million, and repurchased 612,270 shares for $78 million, leaving about $1,654 million under its 2024 repurchase program. Inventory days on hand rose to 120 from 107, which the company attributed to strategic purchases to reduce tariff-related risk, and the timing of any further tariff refunds remains uncertain.
Fiscal 2026 Outlook
Management raised fiscal 2026 guidance to revenue of $7.49 billion to $7.51 billion, or 5.8% to 6% core growth. Non-GAAP earnings per share are expected at $6.18 to $6.21 including the tariff refund benefit, or $6.12 to $6.15 excluding it. The operating cash flow range of $1.6 billion to $1.7 billion was unchanged, and capital expenditures are expected near $450 million, largely for advanced therapeutics capacity.
For the fiscal fourth quarter, the company expects revenue of $1.98 billion to $2 billion, including about $23 million from Biocare, and non-GAAP earnings per share of $1.71 to $1.74, with no further tariff refund benefit assumed. It expects roughly flat advanced therapeutics growth against a tough comparison, and plans to begin generating revenue from its new Train C facility next spring. These are company estimates, and the company calls tariffs and Middle East tensions dynamic.






Please wait processing your request...